May 18, 2009 McLean, Virginia
EBI Announces Start of Phase 2 Human Clinical Trials on Renal Protection
May 12, 2009 McLean, Virginia
Dr. Jeffrey Gelfand, M.D. Joins Scientific Advisory Board of EBI
February 10, 2009 McLean, Virginia
EBI Secures a $5 Million Round of Financing
November 10, 2008 Philadelphia, Pennsylvania
Scientists Report on a Novel Therapeutic Agent to Prevent Acute Renal Failure at the American Society of Nephrology's Annual Meeting
October 30, 2008 Washington, D.C.
Support for EBI's Renoprotective Drug Presented at Annual ICAAC/IDSA Meeting
April 1, 2008 Manchester, United Kingdom
Epistem to Provide Preclinical Efficacy Testing Services for Exponential Biotherapies
January 15, 2008 McLean, Virginia
EBI Announces Early Results of Radiation Protection Experiments
May 2, 2007 McLean, Virginia
Michael J. Brownstein, M.D., Ph.D. Appointed Chief Scientific Officer of Exponential Biotherapies, Inc.
February 15, 2007 McLean, Virginia
EBI Announces 3 new Directors
January 31, 2007 McLean, Virginia
EBI Completes a $10.5 Million Private Placement
April 4, 2006 McLean, Virginia
EBI Completes an $8.75 Million Round of Financing
March 10, 2006 McLean, Virginia
EBI Announces Completion of EA-230 Phase IA Multi-Dose Human Safety Trials
November 21, 2005 Boston, Massachusetts
EBI Announces Zsolt Harsanyi, Ph.D., Chairman & CEO, Has Been Elected to The Board of Trustees of the CBR Institute For Biomedical Research, Inc. of Harvard Medical School
October 20, 2005 Washington, D.C.
EBI Announces Completion of EA-230 Phase IB Single Dose Human LPS Challenge
October 17, 2005 Washington, D.C.
EBI Closes $6.25 Million in Equity Financing
August 30, 2005 Washington, D.C.
EBI Announces Completion of EA-230 Phase IA Single Dose Human Safety Trials